Literature DB >> 11720448

Drug-induced alterations in tumour perfusion yield increases in tumour cell radiosensitivity.

K L Bennewith1, R E Durand.   

Abstract

The perfusion of human tumour xenografts was manipulated by administration of diltiazem and pentoxifylline, and the extent that observed changes in tumour perfusion altered tumour radiosensitivity was determined. 2 tumour systems having intrinsically different types of hypoxia were studied. The responses of SiHa tumours, which have essentially no transient hypoxia, were compared to the responses of WiDr tumours, which contain chronically and transiently hypoxic cells. We found that relatively modest increases in net tumour perfusion increased tumour cell radiosensitivity in WiDr tumours to a greater extent than in SiHa tumours. Moreover, redistribution of blood flow within WiDr tumours was observed on a micro-regional level that was largely independent of changes in net tumour perfusion. Through fluorescence-activated cell sorting coupled with an in vivo-in vitro cloning assay, increases in the radiosensitivity of WiDr tumour cells at intermediate levels of oxygenation were observed, consistent with the expectation that a redistribution of tumour blood flow had increased oxygen delivery to transiently hypoxic tumour cells. Our data therefore suggest that drug-induced changes in tumour micro-perfusion can alter the radiosensitivity of transiently hypoxic tumour cells, and that increasing the radiosensitivity of tumour cells at intermediate levels of oxygenation is therapeutically relevant.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11720448      PMCID: PMC2363939          DOI: 10.1054/bjoc.2001.2123

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  30 in total

1.  Regional blood flow by fractional distribution of indicators.

Authors:  L A SAPIRSTEIN
Journal:  Am J Physiol       Date:  1958-04

Review 2.  Calcium channels and calcium channel antagonists.

Authors:  D A Greenberg
Journal:  Ann Neurol       Date:  1987-04       Impact factor: 10.422

3.  Increase in tumor oxygenation and radiosensitivity caused by pentoxifylline.

Authors:  C W Song; T Hasegawa; H C Kwon; J C Lyons; S H Levitt
Journal:  Radiat Res       Date:  1992-05       Impact factor: 2.841

4.  Characterization of the WIDR: a human colon carcinoma cell line.

Authors:  P Noguchi; R Wallace; J Johnson; E M Earley; S O'Brien; S Ferrone; M A Pellegrino; J Milstien; C Needy; W Browne; J Petricciani
Journal:  In Vitro       Date:  1979-06

5.  Pentoxifylline: its pharmacokinetics and ability to improve tumour perfusion and radiosensitivity in mice.

Authors:  D J Honess; I F Dennis; N M Bleehen
Journal:  Radiother Oncol       Date:  1993-09       Impact factor: 6.280

6.  Studies on the exchange of fluids between host and tumor. II. The blood flow of hepatomas and other tumors in rats and mice.

Authors:  P M GULLINO; F H GRANTHAM
Journal:  J Natl Cancer Inst       Date:  1961-12       Impact factor: 13.506

7.  Modulation of tumor hypoxia by conventional chemotherapeutic agents.

Authors:  R E Durand; N E LePard
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-06-15       Impact factor: 7.038

8.  Use of a carbocyanine dye as a marker of functional vasculature in murine tumours.

Authors:  M J Trotter; D J Chaplin; P L Olive
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

9.  Cell selection from a murine tumour using the fluorescent probe Hoechst 33342.

Authors:  D J Chaplin; R E Durand; P L Olive
Journal:  Br J Cancer       Date:  1985-04       Impact factor: 7.640

10.  Changes in tumour blood flow, oxygenation and interstitial fluid pressure induced by pentoxifylline.

Authors:  I Lee; Y Boucher; T J Demhartner; R K Jain
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

View more
  1 in total

1.  Transiently hypoxic tumour cell turnover and radiation sensitivity in human tumour xenografts.

Authors:  Brennan J Wadsworth; Che-Min Lee; Kevin L Bennewith
Journal:  Br J Cancer       Date:  2022-01-14       Impact factor: 9.075

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.